While demonstrating the feasibility of LAM as a TB biomarker, the sensitivity/specificity profile led the World Health Organization (WHO) to limit its endorsement to a subgroup of HIV+ adult in-patients with advanced disease and CD4+ T-cell counts <100 cell/μL and signs and symptoms of active TB disease [11]. The gene discussed is CD4; the disease is tuberculosis.